Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs TRXE 002 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Novogen
- 11 Dec 2017 Novogen company name has changed to Kazia Therapeutics Limited.
- 07 Aug 2017 According to a Novogen media release, the company anticipates MTD results in the first quarter of 2018 and the exploratory efficacy data from the additional patients will be available later in 2018.
- 10 Jun 2017 Biomarkers information updated